FDA grants orphan drug designation to ImMucin in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted an Orphan Drug Designation to ImMucin for the treatment of multiple myeloma, developed by Vaxil Bio.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login